MindBio Therapeutics Corp
CNSX:MBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SZSE:300026
|
CN |
|
CROSSTEC Group Holdings Ltd
HKEX:3893
|
HK |
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CA |
M
|
MindBio Therapeutics Corp
CNSX:MBIO
|
6m CAD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.2B USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.2B USD |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
Market Distribution
Other Profitability Ratios
MindBio Therapeutics Corp
Glance View
Mindbio Therapeutics Corp. engages in developing psychedelic medicines to treat medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2023-05-05. The firm is focused on creating novel and emerging treatments for mental health conditions and is conducting lysergic acid diethylamide (LSD)-microdosing human clinical trials. The company has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development. The company has completed Phase I clinical trials microdosing LSD in 80 patients, has a Phase II clinical trial in development microdosing LSD in patients with major depressive disorder, and has a Phase II clinical trial in development microdosing LSD in late-stage cancer patients experiencing existential distress. The firm invests in research that forms the basis for developing novel and clinically proven treatments, including digital technologies and interventions, to treat debilitating health conditions such as depression, anxiety, and other related mental health conditions.
